NASDAQ:AMLX Amylyx Pharmaceuticals Q2 2025 Earnings Report $7.72 -0.31 (-3.86%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$7.56 -0.16 (-2.07%) As of 08/1/2025 06:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Amylyx Pharmaceuticals EPS ResultsActual EPSN/AConsensus EPS -$0.43Beat/MissN/AOne Year Ago EPSN/AAmylyx Pharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AAmylyx Pharmaceuticals Announcement DetailsQuarterQ2 2025Date8/7/2025TimeBefore Market OpensConference Call DateThursday, August 7, 2025Conference Call Time8:00AM ETConference Call ResourcesEarnings HistoryCompany Profile Amylyx Pharmaceuticals Earnings HeadlinesAmylyx Pharmaceuticals: A High-Risk Pipeline With Strong Upside PotentialJuly 21, 2025 | seekingalpha.comAmylyx Pharmaceuticals Shares Promising Avexitide Data for Post-Bariatric Hypoglycemia at ENDO 2025, Phase 3 Enrollment Nears CompletionJuly 15, 2025 | finance.yahoo.comJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% of his time focused on AI… but Nova is only part of the story. Behind the scenes, Amazon has been quietly investing in a breakthrough called “Helios” tech—a core enabler of the $40 trillion AI revolution. While Nova grabs headlines, this technology could be what truly transforms Amazon’s future. But one tiny startup—not Amazon—may offer the bigger upside.August 2 at 2:00 AM | Stansberry Research (Ad)Amylyx presents new exploratory analyses from avexitide trials for PBHJuly 15, 2025 | finance.yahoo.comAMYLYX ALERT: Bragar Eagel & Squire, P.C. is Investigating Amylyx Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmJuly 14, 2025 | globenewswire.comAmylyx Drug Slashes Sugar Spikes Post-Weight Loss SurgeryJuly 14, 2025 | benzinga.comSee More Amylyx Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Amylyx Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Amylyx Pharmaceuticals and other key companies, straight to your email. Email Address About Amylyx PharmaceuticalsAmylyx Pharmaceuticals (NASDAQ:AMLX), a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.View Amylyx Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Amazon's Earnings: What Comes Next and How to Play ItApple Stock: Big Earnings, Small Move—Time to Buy?Microsoft Blasts Past Earnings—What’s Next for MSFT?Visa Beats Q3 Earnings Expectations, So Why Did the Market Panic?Spotify's Q2 Earnings Plunge: An Opportunity or Ominous Signal?RCL Stock Sinks After Earnings—Is a Buying Opportunity Ahead?Amazon's Pre-Earnings Setup Is Almost Too Clean—Red Flag? Upcoming Earnings Palantir Technologies (8/4/2025)Vertex Pharmaceuticals (8/4/2025)Axon Enterprise (8/4/2025)MercadoLibre (8/4/2025)Williams Companies (8/4/2025)ONEOK (8/4/2025)Simon Property Group (8/4/2025)Advanced Micro Devices (8/5/2025)Marriott International (8/5/2025)Amgen (8/5/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
